Follow the Money: Rheumatoid Arthritis Therapy, Novel Next-Gen Biosensor, More

Strand Therapeutics announced $153 million in Series B funding. The funding will advance Strand’s pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently announced promising initial Phase 1 clinical data for patients with advanced solid tumors, noting multiple RECIST responses (including cases of complete response and complete metabolic response), multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients.

$140M: Series C and D for Rheumatoid Arthritis Therapy 

SetPoint Medical has raised $140 million in private financing, which includes $25 million in the second tranche of its Series C financing and $115 million in its Series D financing. Proceeds will support commercialization of the SetPoint System, a first-of-its-kind neuroimmune modulation therapy for adults living with moderate-to-severe rheumatoid arthritis (RA), as well as advancement of the company’s pipeline in other autoimmune conditions.

$132M: Series B for Alpha Radioligand Therapies 

ARTBIO closed a $132 million Series B financing. The funds will support the advancement of ARTBIO's pipeline, including its lead program, AB001, for metastatic castration-resistant prostate cancer, through Phase II clinical trials, and enable continued expansion of the company's supply chain. The company plans to rapidly advance its manufacturing network infrastructure to supply global clinical trials and commercialization.

$55.7M: Series D for Cell and Gene Therapy Platform 

METiS Technologies successfully completed its RMB 400 million Series D financing round. The new capital will be used to accelerate METiS' core strategic initiatives, including automation upgrades to its proprietary platform, in-house pipeline development, expansion of global partnerships, and recruitment of talent. METiS launched the OpenCGT platform—designed to address key challenges in precision nanodelivery, reduce costs and complexity, and enable the clinical translation of next-generation cell and gene therapies. The OpenCGT platform bridges the gap between foundational research in leading academic institutions and major hospitals, and translational work by biotech firms. Its inaugural project is to enable AccurEdit Therapeutics to develop a liver-targeted CRISPR gene-editing therapy using mRNA-LNP delivery.

$44M: Series C for Reproductive Care 

Gameto announced the completion of a $44 million Series C financing round. The funding enables Gameto to complete the ongoing Phase 3 trial for its lead program, Fertilo, and file for regulatory approvals globally. The therapy uses engineered ovarian support cells (OSCs) derived from iPSCs to mature eggs outside the body, reducing the standard ovarian stimulation protocol from two weeks of daily hormone injections to 2-3 days. The Fertilo Phase 3 trial is the first randomized, controlled, double-blind study evaluating ex vivo egg maturation.

$40.6M: Series B for CRISPR-Medicines Targeting Antimicrobial Resistance 

SNIPR announced the close of a $40.6 million Series B raise. This funding will support the development of a CRISPR-Cas therapy specifically targeting airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF). Additionally, it will enable the advancement of a CRISPR-based microbial intervention designed to eliminate antibiotic resistance genes in humans across various bacterial species and environments. The funding will also further the clinical development of the company’s CRISPR-based product, SNIPR001, in patients with hematologic cancer, including the ongoing phase 1b trial.

$35M: Series A for Longevity Protein Program 

Jocasta Neuroscience has raised $35 million in Series A financing. The funds will be used to support development of Jocasta's lead asset, a proprietary formulation of the a – Klotho protein, JN-0413, through Phase 1 development (including both the Single Ascending Dose and Multiple Ascending Dose studies), with an IND submission slated for Q4 2026. a - Klotho is a protein therapeutic targeting cognitive decline in neurodegenerative diseases.

$20M: Series A for Skin Longevity 

OneSkin has closed its Series A investment round, bringing total funding for the brand to $20 million. The funds will fuel accelerated research and novel formulas, which deliver expanded longevity solutions and rewrites a new way forward for the anti-aging skincare industry. The funding will also power an increase in human capital focused on growth opportunities and new sales channels for the business, creating more accessible pathways for consumers to access OneSkin's advanced technologies.

$20M: Financing for Claromer Drug Candidates 

Maxwell Biosciences has closed a $20 million financing round to support Maxwell's upcoming FDA clinical trials, advance AI-driven R&D, and help expand commercialization in multiple other industries in which nontoxic antiseptics are highly valued, such as cosmetics, cleaning sprays and coatings. Claromers are shelf-stable synthetic small molecules that mimic the human innate immune system to target and destroy viruses, bacteria, fungi and biofilms—without harming healthy tissue. These novel compounds offer a powerful broad-spectrum approach that preserves the body's natural microbial balance, a key limitation of conventional antibiotics and antifungals.

$19M: Series A for Novel Next-Gen Biosensor 

Sava Technologies announced $19 million in Series A funding following promising results from its clinical trial. The funds will help Sava accelerate regulatory approval and commercialization of its next-generation wearable. The team has developed a multi-molecule biosensor capable of detecting biomarkers just beneath the skin, in real-time. This proprietary technology is powering their first product—a pain-free Continuous Glucose Monitor (CGM) that streamlines molecular insights in real-time to your phone, at a fraction of the cost of current alternatives. Early results from the first 25 patients showed Sava’s proprietary technology delivered reliable, accurate glucose readings for up to 10 days of continuous wear.

$10M: Series A for New Drug Application for Anaphylaxis 

Belhaven Biopharma closed an oversubscribed Series A financing round. Proceeds will enable Belhaven to complete the clinical development and commercial manufacturing of Nasdepi and prepare for a New Drug Application (NDA) submission to the US Food and Drug Administration (FDA). Nasdepi is poised to be the first dry powder, needle-free, and heat-stable epinephrine therapy designed for the emergency treatment of anaphylaxis to reach the market.

$8M: Series C for Chromosomal Structural Rearrangements 

KROMATID closed its Series C funding round, raising a total of $8 million. The funds will fuel expansion of KROMATID's proprietary platforms for detecting chromosomal structural rearrangements, scale operations to meet growing global demand, and advance strategic partnerships with pharmaceutical and academic leaders in cell and gene therapy.